Robert Kempton Email and Phone Number

Global vaccines lead for the 1st respiratory syncytial virus (RSV) vaccine for older adults, with accountability for the global launch and life cycle management of Arexvy - with expected Peak Year Sales approx £3billion.

Responsible for our Vaccines Commercial Strategy in Europe, delivering approx US$2.5 billion in sales across the portfolio.

General manager and CEO for GSK Korea, responsible for the Pharmaceutical (Respiratory, HIV, Urology, Oncology) and Vaccines business. GSK Korea is a Tier 2 / mid-size market with strategic importance to GSK. It has a sizeable P&L (approx US$ 300-350 in 2023), over 400 employees, and operates in a complex and highly regulated business environment. Key achievements: Leading the organizational transformation strategy (portfolio resourcing, culture, capabilities, leadership, talent, and governance) and setting new standards in how we operate. Accelerated growth in 2023, with 50%+ revenue growth in 2023 vs 2022 and over target delivery. Our medicines and vaccines reached over 2 million Koreans in 2023. Responsibilities include: 1) Inspiring the GSK Korea team, creating a culture where our ~400 employees can thrive, and deliver value to our patients, physicians, and shareholders. 2) Ensuring patients have access to GSK medicines and vaccines in Korea 3) Maintaining a strong and responsible link with the community where we operate (regulators, policymakers, industry associations, and NGOs).4) Custodian of GSK’s reputation. As GM and the legal representative for the company, I hold myself and my team accountable for the GSK values, policies, ethical standards, and local laws, to ensure we operate with the highest level of integrity.Key Brands include TRELEGY®, RELVAR®, ANORO®, DUODART®, DOVATO®, SHINGRIX®, JEMPERLI®Board member at KRPIA (industry association) and sponsor of the Market Access Committee.

Team leader, with commercial accountability for a portfolio of late-stage (Phase 2) specialty products in Infectious Diseases (Antibiotics and Hep B), Hepatology (PBC) in line with GSK's R&D strategy to focus on the “immune and genetically validated targets”. Responsible for a team of Snr Global Marketing Directors who the long-range forecast, develop commercial and payer strategies, business development, and disease strategies - working in collaboration with R&D leadership. Pipeline value upwards of $4 billion.

A 2nd line leader, with responsibility for sales of GSK's ELLIPTA portfolio (TRELEGY®, BREO®, and ANORO®), in the North and South Carolina Region. The team included approx 90 sales professionals selling in asthma and COPD markets. Demonstrated consistent above nation growth in market share, across all products, and above nation engagement scores.

US Marketing Lead for the Dolutegravir Franchise (TIVICAY® and TRIUMEQ®) – a US$2-3 billion dollar HIV portfolio in the US. Responsibility for the US strategic marketing direction and implementation of the brand tactics and POA, and 4 teams: 1. HCP inline Marketing 2. Patient Marketing (DTP) 3. Digital Marketing 4. Pipeline Marketing

Led the Commercial Operations team for the launch of TIVICAY® and TRIUMEQ®, with responsibility for 3 teams.:1. Insight and Analytics2. Commercial Training3. Sales Operations I was a member of the North American Leadership Team, and Chief of Staff to the President and SVP for ViiV Healthcare North America.

Led a cross-functional agency team in all aspects of the strategic planning process, marrying strategy with in-depth marketplace insight to serve the marketing communication needs of US and global pharmaceutical clients. Role included consulting, brand strategy planning, leading workshops, market research, attendance of internal client meetings and brand stewardship across all channels. Key clients included: - Gilead Sciences: Led the global and US brand strategy and positioning development for the launch of a new HIV blockbuster brand (STRIBILD®). - Biogen Idec: Led the global brand strategy and message development for a mature blockbuster MS brand (AVONEX®), including repositioning development and new product planning for TECFIDERA® & PEGASYS®).The prior name of the company was Palio / Inventiv.

Led business development activities for a discovery and clinical stage pharmaceutical company mainly focused in Oncology. Responsible for leading the product development team to provide commercial input; cultivating collaborations with “Big Pharma”; negotiating partnership agreements; and serving as company spokesperson at international partnering conferences (BioPharm).

Led my own brand strategy consultancy, designing and building unique processes for brand strategy development. Clients included pharmaceutical, retail, and technology companies. Specific services included: Customer Insight Discovery, Scenario Planning, Brand Strategy and Positioning Development, Brand Management Services and Executive Management Workshops.

See individual descriptions below

Lead a team of sales reps and payer account managers to deliver regional sales targets for depression and insomnia brands (Lexapro® and Circadin®) in a complex and highly regulated market. Led a “culture change” within my team to be more focused on sales outcomes rather than activity. *Moved to USA Q1 2009

Led strategic brand repositioning for a major Parkinson’s brand (Azilect®). Managed all aspects of strategic planning and tactics for the brand, including development of annual business plans, branded communications, advertising, and KOL advocacy. Chaired cross-functional brand team, proactively managing a complex co-promotion relationship with Teva Pharmaceuticals.

Led and executed multiple launches for Depression and Alzheimer’s brands (LEXAPRO® and NAMENDA®) across 9 Asian markets, including China and Korea. Sales in Asia region increased 70% during 3.5 yr tenure. In China, I led the development of the NAMEDA® launch plan, in collaboration with our new Lundbeck China subsidiary and partnered with Xian-Janssen on LEXAPRO® marketing plans. In addition to launch planning with local markets, I also executed all "Asia" regional marketing tactics including: 3 major Asia based international symposia; the first non-promotional ‘Lundbeck Institute HCP Workshop’; 2 Asia External Expert meetings to build advocacy; introduced an ECRM system; Regional Level Copy approval processes for marketing materials; management programs for country managers in collaboration with local Universities and represented the region on the International Brand Board at Lundbeck HQ in Denmark.

Worked within cross-functional brand team to deliver marketing objectives for depression brand (Lexapro®). Responsibilities included: campaign development, customer symposium management, and sales force training.

Led market research and analytical projects, for both Depression and Alzheimer’s brands. Initiated and developed the 1st UK Competitor Intelligence Unit, a formalized mechanism to continuously gather information on Lundbeck’s competitors and develop effective responses to their messaging (LEXAPRO® and NAMENDA®). Analyzed & reported new product KPIs to Snr management by monitoring parameters via market research audits/techniques

Met demanding call rate, Celexa® sales targets and achieved formulary (guideline) approval for insomnia brand (Sonata®). Strong performance in medical represenative role led to a promotion to the marketing department.